These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 16507376

  • 1. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
    Dunner DL, Lipschitz A, Pitts CD, Davies JT.
    Clin Ther; 2005 Dec; 27(12):1901-11. PubMed ID: 16507376
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [Abstract] [Full Text] [Related]

  • 3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 4. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD.
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dubé EM.
    J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
    [Abstract] [Full Text] [Related]

  • 7. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea.
    Pae CU, Bahk WM, Jon DI, Lee SY, Yoon BH, Min KJ.
    Hum Psychopharmacol; 2007 Aug; 22(6):351-9. PubMed ID: 17487934
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
    Chaudhry HR, Qureshi Z, Tareen IA, Yazdani I.
    J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
    [Abstract] [Full Text] [Related]

  • 10. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial.
    Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M.
    Psychosom Med; 2004 Nov; 66(5):707-13. PubMed ID: 15385695
    [Abstract] [Full Text] [Related]

  • 11. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.
    Sheehan DV, Burnham DB, Iyengar MK, Perera P, Paxil CR Panic Disorder Study Group.
    J Clin Psychiatry; 2005 Jan; 66(1):34-40. PubMed ID: 15669886
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial.
    Xiao L, Zhu X, Gillespie A, Feng Y, Zhou J, Chen X, Gao Y, Wang X, Ma X, Gao C, Xie Y, Pan X, Bai Y, Xu X, Wang G, Chen R.
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
    Yu YM, Gao KR, Yu H, Shen YF, Li HF.
    J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
    [Abstract] [Full Text] [Related]

  • 15. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS, Cooper JA, Huusom AK, Hindmarch I.
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [Abstract] [Full Text] [Related]

  • 16. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S, Olivieri L, Di Loreto G, Dionisio P.
    Curr Med Res Opin; 2005 Aug; 21(8):1139-46. PubMed ID: 16083521
    [Abstract] [Full Text] [Related]

  • 17. Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea.
    Higuchi T, Hong JP, Jung HY, Watanabe Y, Kunitomi T, Kamijima K.
    Psychiatry Clin Neurosci; 2011 Dec; 65(7):655-63. PubMed ID: 21895859
    [Abstract] [Full Text] [Related]

  • 18. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA, Snavely DB, Hargreaves RJ, Szegedi A, Lines C, Reines SA.
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [Abstract] [Full Text] [Related]

  • 19. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
    Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.
    J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
    [Abstract] [Full Text] [Related]

  • 20. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.